SG11201707127VA - Method of treating cancer associated with a ras mutation - Google Patents

Method of treating cancer associated with a ras mutation

Info

Publication number
SG11201707127VA
SG11201707127VA SG11201707127VA SG11201707127VA SG11201707127VA SG 11201707127V A SG11201707127V A SG 11201707127VA SG 11201707127V A SG11201707127V A SG 11201707127VA SG 11201707127V A SG11201707127V A SG 11201707127VA SG 11201707127V A SG11201707127V A SG 11201707127VA
Authority
SG
Singapore
Prior art keywords
treating cancer
cancer associated
ras mutation
ras
mutation
Prior art date
Application number
SG11201707127VA
Inventor
Lan Huang
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56878960&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201707127V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of SG11201707127VA publication Critical patent/SG11201707127VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SG11201707127VA 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation SG11201707127VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562129654P 2015-03-06 2015-03-06
US201562249788P 2015-11-02 2015-11-02
PCT/US2016/020390 WO2016144635A1 (en) 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation

Publications (1)

Publication Number Publication Date
SG11201707127VA true SG11201707127VA (en) 2017-09-28

Family

ID=56878960

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202008673WA SG10202008673WA (en) 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation
SG11201707127VA SG11201707127VA (en) 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202008673WA SG10202008673WA (en) 2015-03-06 2016-03-02 Method of treating cancer associated with a ras mutation

Country Status (16)

Country Link
US (4) US10238650B2 (en)
EP (1) EP3265090A4 (en)
JP (1) JP6769982B2 (en)
KR (1) KR102626155B1 (en)
CN (1) CN107530341B (en)
AU (2) AU2016229294B2 (en)
BR (1) BR112017018954A2 (en)
CA (1) CA2978567A1 (en)
CL (1) CL2017002241A1 (en)
HK (2) HK1250008A1 (en)
IL (1) IL254256A0 (en)
MX (1) MX2017011374A (en)
MY (1) MY190034A (en)
RU (1) RU2736045C2 (en)
SG (2) SG10202008673WA (en)
WO (1) WO2016144635A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102626155B1 (en) * 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. RAS omitted
EP3265091A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating a brain tumor
KR20180027563A (en) 2015-07-13 2018-03-14 비욘드스프링 파마수티컬스, 인코포레이티드. Flinabuled composition
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
JP2020514412A (en) 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Methods for reducing neutropenia
JP2019019094A (en) * 2017-07-19 2019-02-07 学校法人福岡大学 Mutant kras-related signal inhibitory composition
CN109498627B (en) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 Pharmaceutical composition for treating tumors and application thereof
WO2019147615A1 (en) * 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
EP3773724A2 (en) * 2018-04-12 2021-02-17 UMC Utrecht Holding B.V. Drug combinations for use in the treatment of ras-mutant cancer
CN112543636B (en) * 2018-06-01 2024-03-01 大连万春布林医药有限公司 Compositions and methods for treating cancers associated with EGFR mutations
CN109652535A (en) * 2019-01-30 2019-04-19 上海安甲生物科技有限公司 Identify human thyroid tubercle good pernicious kit and its application method and application
KR102222693B1 (en) * 2019-04-04 2021-03-04 금정제약 주식회사 Novel uses of H-REV107 derived peptide
US20230000867A1 (en) 2019-11-28 2023-01-05 Inxmed (Nanjing) Co., Ltd. Use of bi853520 in cancer treatment
CN111534599A (en) * 2020-06-18 2020-08-14 重庆浦洛通基因医学研究院有限公司 Thyroid cancer auxiliary molecular diagnosis kit and using method thereof
WO2022216908A1 (en) * 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
WO2023060200A1 (en) * 2021-10-07 2023-04-13 Beyondspring Pharmaceuticals, Inc. Methods for treating cancers and tumors
WO2024006678A1 (en) * 2022-06-26 2024-01-04 Biohaven Therapeutics Ltd. Methods of treating glioblastoma with prodrugs of riluzole
WO2024088275A1 (en) * 2022-10-25 2024-05-02 中国科学院上海药物研究所 Use of naphthylamide compound in treating drug-resistant tumors
CN117919235A (en) * 2022-10-25 2024-04-26 上海润石医药科技有限公司 Application of naphthalamide compound in treating KRAS mutation related diseases

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164B1 (en) 1970-12-29 1975-04-10
EP0022229B1 (en) 1979-06-29 1982-12-08 The Wellcome Foundation Limited Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof
IT1193786B (en) 1980-12-18 1988-08-24 Wellcome Found ETHEREAL COMPOUNDS EQUIPPED WITH MITIGATING ACTIVITY OF INTERMEDIATE HEMOGLOBINOPATHIES AND PROCEDURE FOR THEIR PREPARATION
JPS58167304A (en) 1982-03-24 1983-10-03 松下電器産業株式会社 Refuse disposal plant
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (en) 1990-10-31 1993-10-05 Toray Ind Inc Medicine for thrombocytopenia
JPH059164A (en) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd Production of optically active mandelonitrile derivative
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
DE69306545T2 (en) 1992-10-01 1997-04-03 Wellcome Found Tucaresol as an immunopotentiator
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
JP2880292B2 (en) 1992-11-27 1999-04-05 ナプロ バイオセラピューティクス，インコーポレイテッド Injectable composition
JPH0725858A (en) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd Piperazine derivative
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (en) 1996-09-04 2001-02-05 新日本製鐵株式会社 Novel antitumor substance, microorganism and method for producing the substance, and cell cycle inhibitor and antitumor agent containing the substance as active ingredient
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
EP2201944B1 (en) 1997-11-21 2012-05-23 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression
WO1999038844A1 (en) 1998-01-29 1999-08-05 Aventis Pharmaceuticals Products Inc. Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
PL343249A1 (en) 1998-03-26 2001-07-30 Shionogi & Co Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
FR2784988B1 (en) 1998-10-23 2002-09-20 Adir NOVEL DIHYDRO AND TETRAHYDROQUINOLEINIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6936704B1 (en) 1999-08-23 2005-08-30 Dana-Farber Cancer Institute, Inc. Nucleic acids encoding costimulatory molecule B7-4
PT1210428E (en) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, a receptor for b7-4, and uses therefor
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6972289B1 (en) 2000-01-18 2005-12-06 Nereus Pharmaceuticals, Inc. Cell division inhibitor and a production method thereof
EP1265840A2 (en) 2000-03-17 2002-12-18 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
EP1282609B1 (en) 2000-05-09 2008-12-17 AngioRx Corporation Piperazinedione compounds
WO2002064592A1 (en) 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US20030082140A1 (en) * 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
KR20050000544A (en) 2002-05-17 2005-01-05 아방티 파르마 소시에테 아노님 Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DE60316688T2 (en) * 2002-08-02 2008-07-17 Nereus Pharmaceuticals, Inc., San Diego DEHYDROPHENYLAHISTINES AND ANALOGS THEREOF AND A PROCESS FOR THE PRODUCTION OF DEHYDROPHENYLAHISTINES AND ANALOGUE THEREOF
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
SE0202429D0 (en) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
CN101899114A (en) 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
NZ548659A (en) 2004-02-04 2011-01-28 Nereus Pharmaceuticals Inc Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7999106B2 (en) 2004-04-19 2011-08-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form I
DE202004018940U1 (en) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Snap closure, snap-fastener tape and resealable bag
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (en) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 Human monoclonal antibodies to programmed death ligand 1(PD-L1)
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP1973569B1 (en) 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ES2527412T3 (en) 2007-02-15 2015-01-23 Mannkind Corporation Method to increase the response of T lymphocytes
ES2389828T3 (en) 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Compositions comprising SPARC polypeptides
US20090170837A1 (en) * 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
CN101909693A (en) 2008-01-08 2010-12-08 百时美施贵宝公司 Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
TWI461423B (en) 2008-07-02 2014-11-21 Astrazeneca Ab Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases
PE20120341A1 (en) 2008-12-09 2012-04-24 Genentech Inc ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
US8323634B2 (en) 2009-01-16 2012-12-04 Teva Pharmaceutical Industries Ltd. Stable formulations of highly concentrated recombinant human albumin-human granulocyte colony stimulating factor
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2464218B1 (en) 2009-08-10 2015-05-27 Board of Regents, The University of Texas System Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
MX366955B (en) 2009-09-15 2019-07-31 Bluelink Pharmaceuticals Inc Treatment of cancer.
AU2010310468A1 (en) 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
KR101573109B1 (en) 2009-11-24 2015-12-01 메디뮨 리미티드 Targeted binding agents against b7-h1
CN101766815B (en) 2009-12-31 2012-04-25 胡松华 Application of taxol and taxotere
US20130225424A1 (en) * 2010-03-03 2013-08-29 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (en) 2010-07-28 2012-02-16 Fuji Electric Co Ltd Thin film solar cell and method for manufacturing the same
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US20120214679A1 (en) 2010-11-29 2012-08-23 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (en) 2011-01-07 2013-02-21 Univ China Medical Pharmaceutical composition for treating brain cancer or reducing temozolomide-resistance of brain cancer cells and uses of the same
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2013078537A1 (en) 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
SG10201603059YA (en) 2012-05-09 2016-05-30 Cantex Pharmaceuticals Inc Treatment Of Myelosuppression
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
CN111139256A (en) 2013-02-20 2020-05-12 诺华股份有限公司 Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
WO2014174480A1 (en) 2013-04-24 2014-10-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
EP3003282A1 (en) 2013-06-03 2016-04-13 Novartis AG Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
CA2926771C (en) 2013-10-11 2022-07-05 Beyondspring Pharmaceuticals, Inc. Cancer treatment with combination of plinabulin and taxane
KR20160093012A (en) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP3594359B1 (en) 2013-11-06 2022-05-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Method for subtyping lymphoma types by means of expression profiling
CN104796448B (en) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 The data processing method and device of network system
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
RU148945U1 (en) 2014-07-29 2014-12-20 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) CONVECTIVE BOILER UNIT
WO2016019472A1 (en) 2014-08-08 2016-02-11 Quest Pharmatech Inc. Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
BR112017016902A2 (en) 2015-02-12 2018-03-27 Beyondspring Pharmaceuticals, Inc. pharmaceutical composition, its use and method for treating cancer
KR102626155B1 (en) * 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. RAS omitted
EP3265091A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating a brain tumor
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
CN106279039B (en) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 Deuterated dehydrophenylahistin class compound and preparation method thereof and preparing the application in anti-tumor drug
KR20180027563A (en) 2015-07-13 2018-03-14 비욘드스프링 파마수티컬스, 인코포레이티드. Flinabuled composition
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
JP2020514412A (en) 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Methods for reducing neutropenia
EP3595653B1 (en) 2017-03-13 2023-03-08 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
KR20200116477A (en) 2018-02-01 2020-10-12 비욘드스프링 파마수티컬스, 인코포레이티드. Compositions and methods for reducing chemotherapy-induced neutropenia through administration of plinabulin and G-CSF agents
CN110240592A (en) 2018-03-08 2019-09-17 青岛海洋生物医药研究院股份有限公司 (Z) -3- (3- formoxyl benzylidene) piperazinedione compounds and its application in preparation of anti-tumor drugs
US11590130B2 (en) 2018-04-05 2023-02-28 Noviga Research Ab Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer
CN112543636B (en) 2018-06-01 2024-03-01 大连万春布林医药有限公司 Compositions and methods for treating cancers associated with EGFR mutations
CA3109223A1 (en) 2018-08-16 2020-02-20 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
MX2021005646A (en) 2018-11-14 2021-08-11 Beyondspring Pharmaceuticals Inc Methods of treating cancer using tubulin binding agents.
CN112778155B (en) 2019-11-11 2023-08-11 大连万春布林医药有限公司 Tucarbaryl derivatives and uses thereof
MX2022013808A (en) 2020-05-04 2023-02-09 Beyondspring Pharmaceuticals Inc Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity.

Also Published As

Publication number Publication date
KR102626155B1 (en) 2024-01-17
EP3265090A1 (en) 2018-01-10
CN107530341A (en) 2018-01-02
US20210275524A1 (en) 2021-09-09
MY190034A (en) 2022-03-22
US20190328727A1 (en) 2019-10-31
RU2017131430A (en) 2019-04-09
RU2017131430A3 (en) 2019-08-28
JP2018507249A (en) 2018-03-15
US11045467B2 (en) 2021-06-29
SG10202008673WA (en) 2020-10-29
HK1249052A1 (en) 2018-10-26
CN107530341B (en) 2021-10-01
BR112017018954A2 (en) 2018-05-15
AU2016229294B2 (en) 2021-11-04
AU2016229294A1 (en) 2017-09-28
US11918574B2 (en) 2024-03-05
MX2017011374A (en) 2018-01-23
HK1250008A1 (en) 2018-11-23
IL254256A0 (en) 2017-10-31
US20180036304A1 (en) 2018-02-08
KR20170131491A (en) 2017-11-29
JP6769982B2 (en) 2020-10-14
CL2017002241A1 (en) 2018-04-02
US10238650B2 (en) 2019-03-26
RU2736045C2 (en) 2020-11-11
EP3265090A4 (en) 2018-08-01
AU2021290270A1 (en) 2022-01-27
US10668063B2 (en) 2020-06-02
CA2978567A1 (en) 2016-09-15
US20200289503A1 (en) 2020-09-17
WO2016144635A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
HK1249052A1 (en) Method of treating cancer associated with a ras mutation
HK1251408A1 (en) Methods of treating cancer
HK1258098A1 (en) Methods of treating cancer
ZA201804227B (en) Methods of treating cancer
IL254760A (en) Method for treating cancer
IL304252A (en) Method for treating cancer
IL289947A (en) Method for treating cancer
EP3233089A4 (en) Method of treating cancer with cgamp or cgasmp
IL257691A (en) Method for treating cancer
IL262342A (en) Methods of treating cancer
HK1250944A1 (en) Methods for treating cancer
HK1252692A1 (en) Methods of treating or preventing a proteopathy
HK1250942A1 (en) Methods for treating cancer
HK1250943A1 (en) Methods for treating cancer
GB201521886D0 (en) A method of treating a well
GB201510197D0 (en) Method of treating ovarian cancer